Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy, as measured by recurrence-free survival (RFS), provided by nivolumab plus ipilimumab versus ipilimumab alone and nivolumab alone in participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma.
Critère d'inclusion
- Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse